Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

Multiple Myeloma (MM)

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

Blood Cancer J

Pasvolsky O, Dima D, Feng L, Dong W, Richards T, Davis JA, Afrough A, Vazquez-Martinez M, Sannareddy A, Goel U, Banerjee R, Khouri J, Cervoni F, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Ferreri CJ, Shune L, DeJarnette S, Bhurtel E, Susanibar Adaniya S, Portuguese A, Hosoya H, Mikkilineni L, Kaur G, Rossi A, Herr MM, Schrum D, Lin C, Raza S, Lin Y, Midha S, Omar N, Atarsh S, McGuirk J, Sborov D, Voorhees P, Anwer F, Alsina M, Freeman C, Garfall AL, Razzo BM, Sidana S, Cowan AJ, Anderson LD Jr, Hansen DK, Richard S, Patel KK, Lee HC, Grajales-Cruz A

doi: 10.1038/s41408-025-01297-7

Multiple Myeloma (MM)

Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapy

Br J Haematol

Itzhaki Ben Zadok O, Simitsis P, Jacobson C, Nadeem O, Frigault MJ, Raje N, Duffy C, Costello P, Cruz JD, Looka A, Nohria A

doi: 10.1111/bjh.70216

Further Publications

Chimeric Antigen Receptor T-Cells (CAR T-Cells) in Hematological Malignancies: A Systematic Review and Meta-Analysis of Proportions From Clinical Trials

Am J Hematol

Filippatos C, Kanteli I, Pasipoularidou DG, Gavriatopoulou M, Tentolouris A, Malandrakis P, Sergentanis TN, Terpos E, Ntanasis-Stathopoulos I

doi: 10.1002/ajh.70201

ASH 2025

Multiple Myeloma (MM)

LBA-1: Early MRD negativity following the novel in vivo CAR T-cell therapy KLN-1010 in patients with RRMM

ASH 2025

Lymphoma

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

Multiple Myeloma (MM)

The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

Blood Cancer J

Afrough A, Dima D, Razzo B, Goel U, Sannareddy A, Pasvolsky O, Vazquez-Martinez MA, Ferreri CJ, Banerjee R, Khouri J, Davis JA, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Anwer F, Shune L, DeJarnette S, Grajales-Cruz AF, Ouchveridze E, De Avila G, Susanibar-Adaniya SP, Portuguese AJ, Schrum D, Eberwein E, Hosoya H, Mikkilineni L, Kaur G, McGuirk JP, Rossi A, Herr MM, Castaneda O, Locke FL, Raza S, Lin Y, Atrash S, Sborov DW, Voorhees PM, Richard S, Garfall AL, Sidana S, Patel KK, Hansen DK, Cowan AJ, Anderson LD Jr, Lee HC

doi: 10.1038/s41408-025-01414-6

Multiple Myeloma (MM)

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

Blood Cancer J

Tan CR, Asoori S, Huang CY, Brunaldi L, Popat R, Kastritis E, Martinez-Lopez J, Bansal R, Silva Corraes AM, Chhabra S, Parrondo R, Ailawadhi S, Fotiou D, Dimopoulos MA, Yong K, Mactier C, Lau C, Corona M, Marin AJS, Mian H, Durie BG, Usmani SZ, Martin TG, Lin Y

doi: 10.1038/s41408-025-01259-z

Lymphoma

Allogeneic hematopoietic stem cell transplantation following T-cell-directed immunotherapy failure in B-cell lymphoma: a real-world case series and systematic literature review

Leuk Lymphoma

Kim DH, Cha S, Koh Y, Byun JM

doi: 10.1080/10428194.2026.2638438

Multiple Myeloma (MM)

Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent

Adv Ther

Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martínez López J, Rodríguez-Otero P, Dytfeld D, Jakubowiak A, Schinke C, Besemer B, Anguille S, Manier S, Rasche L, Teipel R, Scheid C, Pawlyn C, Cavo M, Diels J, Ghilotti F, Lau BW, Renaud T, Orel O, Ong F, Ramos DF, Ammann E, Parekh T, Albrecht C, Weisel K, Mateos MV

doi: 10.1007/s12325-025-03409-y

Related content

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapy

Chimeric Antigen Receptor T-Cells (CAR T-Cells) in Hematological Malignancies: A Systematic Review and Meta-Analysis of Proportions From Clinical Trials

LBA-1: Early MRD negativity following the novel in vivo CAR T-cell therapy KLN-1010 in patients with RRMM

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

Allogeneic hematopoietic stem cell transplantation following T-cell-directed immunotherapy failure in B-cell lymphoma: a real-world case series and systematic literature review

Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent